Abbott Laboratories (ABT)
What changed in recent filings
- Revenue +13% YoYQuarter ended Jun 30, 2026
- Institutions — 4 new · 1 added · 1 reduced13F · as of end of 2026 Q2
What changed in recent SEC filings — factual, not a buy/sell recommendation.
Institutions holding Abbott Laboratories
How many of the institutions we track reported holding this stock, quarter by quarter.
2019 Q1: 3 → 2026 Q2: 8 institutions
Counts the 52 institutions we track that reported holding this stock — their full reported holdings, not just the largest positions. Not the total number of institutional holders in the US. Figures are as of quarter-end and disclosed up to 45 days later. Descriptive only — not investment advice.
Which institutions hold Abbott Laboratories
Institutions we track that reported holding this stock in their most recent 13F.
- Dodge & Coxunder 0.01% of portfolio · held as of 2019 Q1 or earlier
- Bridgewater Associates0.02% of portfolio · since 2020 Q3
- Tudor Investment Corp0.09% of portfolio · since 2025 Q4
- Soros Fund Management0.05% of portfolio · since 2026 Q1
- Point72 Asset ManagementNew this quarter0.16% of portfolio · since 2026 Q2
- National Pension Service (Korea)0.25% of portfolio · held as of 2026 Q2 or earlier
- Caisse de depot (Quebec)0.10% of portfolio · held as of 2026 Q2 or earlier
- PRIMECAP Management0.04% of portfolio · held as of 2026 Q2 or earlier
Based on 13F filings — quarter-end holdings, disclosed up to 45 days later. Holding a stock is a fact we report, not a recommendation to buy or sell.
Company overview
Abbott Laboratories. A healthcare conglomerate running medical devices (the FreeStyle Libre glucose sensor), diagnostics, and nutrition.
What is the Biotech & Health sector?
Pharma, biotech, and medical devices. Driven by trial-result events.
Abbott Laboratories is classified under the Biotech & Health sector. See peers below.
Abbott Laboratories key financials
Based on SEC filings · as of Jun 30, 2026
Tap a metric name to see its meaning in the glossary.
Abbott Laboratories vs Biotech & Health sector benchmark
Median of 35 representative sector stocks · SEC filings · factual comparison (not advice)
A simple comparison to the sector benchmark. Higher or lower doesn’t mean good/bad or buy/sell.
ABT revenue by segment summary
SEC 10-Q · segment totals cross-checked against total revenue
2026-06-30 revenue was $12.6B, +13.0% YoY.
The largest segment is Medical Devices, 46.5% of revenue — a concentrated structure.
Recent revenue growth was led mainly by the Diagnostic Products segment (about 63% of the increase).
Full segment weights, YoY changes, and an AI synthesis are available in the detailed analysis.
ETFs holding Abbott Laboratories
Per SEC N-PORT · 2026-05-31 · by weight · factual
ABT on Stocklore
- Revenue by segment — segment weights verified from SEC filings, YoY changes, growth drivers and concentration
- Financials & earnings quality — 6 metrics (FCF conversion, ROIC, net debt, etc.) to gauge profit quality
- 13F institutional holdings — holdings and weight changes of major institutions (45-day delay)
- Sector-relative metrics — Valuation and growth compared with the Biotech & Health average
Peers · Biotech & Health
ABT FAQ
What is Abbott Laboratories (ABT)?
Abbott Laboratories. A healthcare conglomerate running medical devices (the FreeStyle Libre glucose sensor), diagnostics, and nutrition.
What sector is Abbott Laboratories in?
Abbott Laboratories is classified under Biotech & Health. Pharma, biotech, and medical devices. Driven by trial-result events.
What are Abbott Laboratories's key financials?
As of Jun 30, 2026 in SEC filings: Revenue growth (YoY) 8.1%, Operating margin 13.4%, Net margin 11.6%, ROE 12.5%, Debt-to-equity 0.58x. Definitions and interpretation are available on Stocklore.
What are Abbott Laboratories's main revenue segments?
The largest segment is Medical Devices, about 46.5% of revenue. Segment totals are cross-checked against total revenue from SEC filings.
Where can I analyze Abbott Laboratories (ABT) stock?
On Stocklore you can see ABT's financials & earnings quality, 13F institutional holdings, and sector-relative metrics in one place. This page is for information and tools — not a buy/sell recommendation.
Data sources: SEC EDGAR (financials & filings), 13F (institutional holdings, as of quarter-end), market data. This page is for information and analysis tools — it does not recommend buying or selling any security. Investment decisions and responsibility are your own.